A61L2300/606

SI-O-N-P RELATED FABRICATION METHODS, SURFACE TREATMENTS AND USES THEREOF

Disclosed are compositions, methods and processes for fabricating and using a device or other implement including a surface or surfaces having a nanoscale or microscale layer or coating of Si—O—N—P. These coatings and/or layers may be continuous, on the surface or discontinuous (e.g., patterned, grooved), and may be provided on silica surfaces, metal (e.g., titanium), ceramic, and combination/hybrid materials. Methods of producing an implantable device, such as a load-bearing or non-load-bearing device, such as a bone or other structural implant device (load-bearing), are also presented. Craniofacial, osteogenic and disordered bone regeneration (osteoporosis) uses and applications of devices that include at least one surface that is treated to include a nanoscale or microscale layer or coating of Si—O—N—P are also provided. Methods of using the treated and/or coated devices to enhance enhanced vascularization and healing at a treated surface of a device in vivo, is also presented.

Drug-coated balloon catheter and method for the production thereof

The invention relates to a drug-coated balloon catheter and to a method for producing the same. The balloon of the catheter includes (i) a main membrane, and (ii) an asymmetrical polymer membrane which is applied to an outside of the main membrane and into which at least one pharmaceutical active ingredient is introduced.

Polymer coatings containing drug powder of controlled morphology

A method for depositing a coating comprising a polymer and pharmaceutical agent on a substrate, comprising the following steps: discharging at least one pharmaceutical agent in a therapeutically desirable morphology in dry powder form through a first orifice; discharging at least one polymer in dry powder form through a second orifice; depositing the polymer and/or pharmaceutical particles onto said substrate, wherein an electrical potential is maintained between the substrate and the pharmaceutical and/or polymer particles, thereby forming said coating; and sintering said coating under conditions that do not substantially modify the morphology of said pharmaceutical agent.

Cross-linked fatty acid-based biomaterials

Fatty acid-based, pre-cure-derived biomaterials, methods of making the biomaterials, and methods of using them as drug delivery carriers are described. The fatty acid-derived biomaterials can be utilized alone or in combination with a medical device for the release and local delivery of one or more therapeutic agents. Methods of forming and tailoring the properties of said biomaterials and methods of using said biomaterials for treating injury in a mammal are also provided.

BALLOON CATHETERS FOR BODY LUMENS
20230173240 · 2023-06-08 ·

Various embodiments disclosed relate to drug-coated balloon catheters for treating strictures in body lumens and methods of using the same. A drug-coated balloon catheter for delivering a therapeutic agent to a target site of a body lumen stricture includes an elongated balloon having a main diameter. The balloon catheter includes a coating layer overlying an exterior surface of the balloon. The coating layer includes one or more water-soluble additives and an initial drug load of a therapeutic agent.

PROCESS TO COAT A MEDICAL DEVICE SURFACE WITH PEPTIDE-BASED NANOPARTICLES
20230173135 · 2023-06-08 ·

A process of coating a medical device surface with peptide-based nanoparticles with antimicrobial and healing properties; a process to coat a polyurethane (PU) dressing with a cross-linkable polymer adhesive in which was immobilized LL37 peptide conjugated-gold (Au) nanoparticles (LL37NPs) suitable to be applied on wounds. by following the steps of: 1) preparation of medical device surface; 2) coating the surface with a cross-linkable polymer adhesive; 3) spreading of peptide-based nanoparticles over the surface coated with the photo cross-linkable polymer adhesive; 4) exposing the surface coated with the adhesive and the nanoparticles to UV light; 5) placing the surface in phosphate buffer to leach loosely bound nanoparticles. The process described herein may be employed in the production of wound dressings, bandages, PU catheters and medical tubings.

Abradable therapeutic coatings and devices including such coatings

A method of reducing surgical site infection (SSI), using a coated medical device having a tissue penetrating surface and an abradable coating on the medical device comprising at least one antimicrobial agent in the coating.

USE OF SELF-ASSEMBLED ALKYLSILANE COATINGS FOR DRUG DELIVERY APPLICATIONS

The invention relates to self-assembled organosilane- and small molecule drug-containing coatings for resorbable medical implant devices. The coatings can be prepared from precursor compositions containing an organosilane and a small molecule drug, and can be applied to substrates. Prior to applying the coatings, the surfaces of the substrates can be pretreated. The coatings can be functionalized with a binding compound that is coupled with an active component. The coatings can be applied using various techniques and apparatus, more particularly, by a deep-coating process conducted at ambient conditions.

TREATMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH ANTI-PROLIFERATE AND ANTI-INFLAMMATORY DRUGS
20230165840 · 2023-06-01 · ·

Embodiments of the present invention provide a method for treatment of respiratory disorders such as asthma, chronic obstructive pulmonary disease, and chronic sinusitis, including cystic fibrosis, interstitial fibrosis, chronic bronchitis, emphysema, bronchopulmonary dysplasia and neoplasia. The method involves administration, preferably oral, nasal or pulmonary administration, of anti-inflammatory and anti-proliferative drugs (rapamycin or paclitaxel and their analogues) and an additive.

PHARMACEUTICAL PREPARATION AND METHOD OF ITS PRODUCTION AND USE
20170312221 · 2017-11-02 ·

Thus, the present invention provides a composition in powder form comprising highly dispersed silica particles, polymethylsiloxane particles, and a cationic surfactant, wherein at least 25% by weight of the cationic surfactant is present in primary polymethylsiloxane particles carrying the cationic surfactant on their surface and/or in agglomerates of these primary particles.